Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. (Q45904176)
Jump to navigation
Jump to search
scientific article published on 5 February 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. |
scientific article published on 5 February 2014 |
Statements
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials (English)
Frederick J Raal
Marc S Sabatine
Michael J Koren
Gisle Langslet
Harold Bays
Ricardo Dent
Scott M Wasserman
Fannie Huang
Allen Xue
Moetaz Albizem